CF101 May Be Effective for the Treatment of Crohn’s

November 7, 2007

Israeli drugmaker Can-Fite BioPharma’s CF101 might be used to treat Crohn’s disease.

Preclinical studies show the A3 adenosine receptor, which is targeted by CF101, is overexpressed in bowel tissue and peripheral blood mononuclear cells derived from patients with Crohn’s disease. These findings are in line with data showing the efficacy of CF101 as an anti-inflammatory agent in models of inflammatory bowel diseases, Can-Fite said.

The company will proceed with the development of CF101 for the treatment of rheumatoid arthritis and will start a Phase IIb trial for this indication in early 2008.